Vitrolife AB (publ)
Vitrolife AB (publ) Fundamental Analysis
Vitrolife AB (publ) (VTRLY) shows weak financial fundamentals with a PE ratio of -2.32, profit margin of -1.46%, and ROE of -42.15%. The company generates $3.4B in annual revenue with weak year-over-year growth of 2.76%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -115.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze VTRLY's fundamental strength across five key dimensions:
Efficiency Score
WeakVTRLY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentVTRLY trades at attractive valuation levels.
Growth Score
WeakVTRLY faces weak or negative growth trends.
Financial Health Score
ExcellentVTRLY maintains a strong and stable balance sheet.
Profitability Score
WeakVTRLY struggles to sustain strong margins.
Key Financial Metrics
Is VTRLY Expensive or Cheap?
P/E Ratio
VTRLY trades at -2.32 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, VTRLY's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Vitrolife AB (publ) at 1.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -2.29 times EBITDA. This is generally considered low.
How Well Does VTRLY Make Money?
Net Profit Margin
For every $100 in sales, Vitrolife AB (publ) keeps $-1.46 as profit after all expenses.
Operating Margin
Core operations generate -1.41 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-42.15 in profit for every $100 of shareholder equity.
ROA
Vitrolife AB (publ) generates $-45.06 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Vitrolife AB (publ) produces operating cash flow of $622.53M, showing steady but balanced cash generation.
Free Cash Flow
Vitrolife AB (publ) generates strong free cash flow of $493.53M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $3.64 in free cash annually.
FCF Yield
VTRLY converts 4.25% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-2.32
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.39
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.20
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.42
vs 25 benchmark
ROA
Return on assets percentage
-0.45
vs 25 benchmark
ROCE
Return on capital employed
-0.46
vs 25 benchmark
How VTRLY Stacks Against Its Sector Peers
| Metric | VTRLY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -2.32 | 29.45 | Better (Cheaper) |
| ROE | -42.15% | 779.00% | Weak |
| Net Margin | -146.26% | -24930.00% (disorted) | Weak |
| Debt/Equity | 0.20 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 3.40 | 4.65 | Strong Liquidity |
| ROA | -45.06% | -19333.00% (disorted) | Weak |
VTRLY outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Vitrolife AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
95.45%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
7.42%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
75.89%
Industry Style: Defensive, Growth, Innovation
High Growth